| DC4231 |
Linifanib (ABT-869)
Featured
|
ABT-869 is an ATP-competitive, multi-targeted RTK inhibitor that is completely effective against all members of the vascular endothelial growth factor (VEGF) and platelet derived growth factor (PDGF) receptor families. |
|
| DC2088 |
CI-1040 (PD184352)
Featured
|
CI-1040 (PD 184352) is an ATP non-competitive MEK1/2 inhibitor with IC50 of 17 nM. |
|
| DC11107 |
CKD-516 |
CKD-516 (Valecobulin, CKD516) is a potent beta-tubulin polymerization inhibitor with marked antitumor activity both in vitro and in vivo. |
|
| DC7902 |
Fruquintinib (HMPL-013)
Featured
|
Fruquintinib (HMPL-013) is a novel small molecule compound that selectively inhibits vascular endothelial growth factor receptors (VEGFRs). |
|
| DC8247 |
KNK437
Featured
|
KNK437 is a pan-HSP inhibitor, which inhibits the synthesis of inducible HSPs, including HSP105, HSP72, and HSP40. |
|
| DC7186 |
LGK-974
Featured
|
LGK-974 is a potent and specific PORCN inhibitor, and inhibits Wnt signaling with IC50 of 0.4 nM. |
|
| DC10099 |
BGB283 |
Lifirafenib（BGB-283） is a Novel potent and selective RAF Kinase and EGFR inhibitor. |
|
| DC7465 |
MK-2206 2HCl
Featured
|
MK-2206 2HCl is a highly selective inhibitor of Akt1/2/3 with IC50 of 8 nM/12 nM/65 nM, respectively; no inhibitory activities against 250 other protein kinases observed. Phase 2. |
|
| DC9682 |
ML-264
Featured
|
ML264 is a novel small molecule inhibitor of Krüppel-like factor 5 (KLF5). |
|
| DC8474 |
Napabucasin (BBI608)
Featured
|
Napabucasin (BBI608) is an orally-administered small molecule which can block cancer stem cell (CSC) self-renewal and induces cell death in CSCs as well as non-stem cancer cells. |
|
| DC9770 |
NCB-0846
Featured
|
NCB-0846 is a novel,first-in-class,orally TNIK inhibitor with an IC50 value of 21 nM,that have shown strong anti-tumor efficacy against several cancer models. |
|
| DC9777 |
Regorafenib monohydrate（BAY 73-4506）
Featured
|
Regorafenib (BAY 73-4506) is a multi-target inhibitor for VEGFR1, VEGFR2, VEGFR3, PDGFRβ, Kit, RET and Raf-1 with IC50 of 13 nM/4.2 nM/46 nM, 22 nM, 7 nM, 1.5 nM and 2.5 nM, respectively. |
|
| DC1030 |
Regorafenib (BAY73-4506,Fluoro-Sorafenib)
Featured
|
Regorafenib (BAY 73-4506, Fluoro-Sorafenib) is a multi-target inhibitor for VEGFR1, VEGFR2, VEGFR3, PDGFRβ, Kit, RET and Raf-1 with IC50 of 13 nM/4.2 nM/46 nM, 22 nM, 7 nM, 1.5 nM and 2.5 nM, respectively. |
|
| DC7078 |
AZD-8931(Sapitinib)
Featured
|
Sapitinib(AZD8931) is a reversible, ATP competitive inhibitor of EGFR, ErbB2 and ErbB3 with IC50 of 4 nM, 3 nM and 4 nM respectively. |
|
| DC7283 |
SCH-772984
Featured
|
SCH772984 is a novel, specific inhibitor of ERK1/2 with IC50 of 4 nM and 1 nM, respectively. |
|
